Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Vivek Subbiah, MD Profile picture
@VivekSubbiah
Sep 29, 2021 • 32 tweets • 254 min read • Read on X
@TumorBoardTues Looking forward to the discussion on #RET #precisionmedicine
@Aiims1742
@ShaalanBeg
@weoncologists
@RETpositive
@MPishvaian
@StephenVLiu
@DrSteveMartin
@marklewismd
@neerajaiims
@montypal
@ADesaiMD
@jacobadashek
@n8pennell
@VamsiVelcheti
@kyawzinthein86
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 A healthy 56-year-old man presents with neck swelling persisting after 2 weeks of antibiotics. No congenital anamoly. PPD negative. #TumorBoardTuesday
What would you do next ? @marklewismd @StephenVLiu
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 Work-up led to total thyroidectomy+ bilateral neck dissection, a diagnosis of #thyroidcancer with lymph node spread #TumorBoardTuesday @hemoncwarner @RenoHemonc @AMansfieldMD @VamsiVelcheti @kyawzinthein86
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba What do you suspect as diagnosis ⚕️? @AMansfieldMD @jacobadashek @ADesaiMD @PavlosMsaouel @jtmoyers #TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers Pathology revealed Medullary thyroid cancer. Germline testing was negative for RET mutation.
What molecular test will you order using the tumor tissue ? @jacobadashek @Aiims1742 @DralexGva @Alfdoc2 @weoncologists @RETpositive
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 NGS analysis of the resected tumor identified a RET M918T mutation. Additional imaging identified liver metastases. #TumorBoardTuesday @DrSteveMartin @kaushalpar @DrJNaidoo @StephenVLiu
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo He was sequentially treated with six multi-kinase inhibitor regimens: sorafenib [best response of progressive disease (PD)], vandetanib [stable disease (SD)], cabozantinib (SD), MGCD-516 (PD), RXDX-105 [partial response (PR)], & vandetanib+ everolimus (PD).
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo Each treatment was discontinued for disease progression in the liver, most recently with hepatomegaly, large-volume ascites, severe fatigue and markedly decreased performance status.
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo Here are the @myESMO ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research @DrSteveMartin @Annals_Oncology @curijoey @BenWestphalen annalsofoncology.org/article/S0923-…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen Molecular analysis of cell-free DNA 🧪🧬 from blood 🩸taken before vandetanib + everolimus treatment identified the founder RET M918T mutation + a new RET V804M gatekeeper mutation @VamsiVelcheti .
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen What treatment would you start next ❓
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen Patient was started on a selective RET inhibitor (Selpertcatinib or Pralsetinib). CEA and calcitonin levels decreased dramatically, together with resolution of diarrhea, abdominal pain and fatigue, 60 % response of target lesions #tumorboardtuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen New selective RET inhibitors ( Selpercatinib/ Pralsetinib) have activity and favourable toxicity profiles in RET-altered solid tumors #tumorboardtuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen Mini-Tweetorial begins ! #tumorboardtuesday #RET #precisionmedicine
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen RET fusions are seen in NSCLC (2%) and papillary thyroid cancers (PTC; 10%–20%), whereas somatic (60%–90%) or germline (100%) RET mutations are seen in medullary thyroid cancer
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen Advances in Targeting RET-Dependent Cancers @CD_AACR cancerdiscovery.aacrjournals.org/content/10/4/4…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR State-of-the-Art Strategies for Targeting RET-Dependent Cancers @ASCO_Pubs
#TumorBoardTuesday
ascopubs.org/doi/abs/10.120…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs Two selective RET inhibitors have been recently FDA approved for treatment RET altered thyroid and Lung cancers 👉Selpercatinib and Pralsetinib

#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs Precision therapy for RET-altered cancers with RET inhibitors
#TumorBoardTuesday @CellPressNews
@trendscancer cell.com/trends/cancer/…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer Efficacy of Selpercatinib in RET-Altered Thyroid Cancers @NEJM
#TumorBoardTuesday
nejm.org/doi/full/10.10…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study @TheLancetEndo @AMansfieldMD

#TumorBoardTuesday
thelancet.com/journals/landi…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo Both the newly approved RET inhibitor drugs have clinical activity against the gatekeeper RET V804 M mutation
#TumorBoardTuesday
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo Selective RET kinase inhibition with selpercatinib for patients with RET-altered cancers @Annals_Oncology annalsofoncology.org/article/S0923-…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo Precision Targeted Therapy with Pralsetinib or BLU-667 for RET-Driven Cancers @CD_AACR
#TumorBoardTuesday
cancerdiscovery.aacrjournals.org/content/8/7/836
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo Over 40% of patients with RET-mutant Thyroidcancer on selpercatinib, reported clinical meaningful improvements in diarrhea Patient‐Reported Outcomes with Selpercatinib & RET‐Mutant Medullary Thyroid Cancer @OncJournal

#TumorBoardTuesday
theoncologist.onlinelibrary.wiley.com/doi/10.1002/on…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal RET alterations are seen in multiple cancer types and has the potential to be a tissue agnostic target @jacobadashek @ADesaiMD @andreevdrakhlin

#TumorBoardTuesday

mct.aacrjournals.org/content/early/…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers @jacobadashek @ADesaiMD @MCT_AACR mct.aacrjournals.org/content/early/…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer @NEJM

#TumorBoardTuesday
nejm.org/doi/full/10.10…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study @TheLancetOncol

#TumorBoardTuesday
thelancet.com/journals/lanon…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR @TheLancetOncol Tissue agnostic including Cholangiocarcinoma @curecc @MPishvaian 👉 Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.

#TumorBoardTuesday
ascopubs.org/doi/abs/10.120…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR @TheLancetOncol @curecc Tissue agnostic including GI malignancies 👉Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers @MPishvaian @doctorpemm @weldeiry

#TumorBoardTuesday
cancerres.aacrjournals.org/content/81/13_…
@TumorBoardTues @Aiims1742 @ShaalanBeg @weoncologists @RETpositive @MPishvaian @StephenVLiu @DrSteveMartin @marklewismd @neerajaiims @montypal @ADesaiMD @jacobadashek @n8pennell @VamsiVelcheti @kyawzinthein86 @hemoncwarner @RenoHemonc @AMansfieldMD @FordePatrick @PatelOncology @YYElamin @LeciaSequist @LeXiuning @DrNabilSaba @PavlosMsaouel @jtmoyers @DralexGva @Alfdoc2 @kaushalpar @DrJNaidoo @myESMO @Annals_Oncology @curijoey @BenWestphalen @CD_AACR @ASCO_pubs @CellPressNews @trendscancer @NEJM @TheLancetEndo @OncJournal @andreevdrakhlin @GlopesMd @MCT_AACR @TheLancetOncol @curecc @doctorpemm Broad-based genomic profiling is essential to identify actionable oncogenic drivers, including RET fusions
#TumorBoardTuesday @Dr_R_Kurzrock @JAMAOnc

jamanetwork.com/journals/jamao…

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Vivek Subbiah, MD

Vivek Subbiah, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VivekSubbiah

Vivek Subbiah, MD Profile picture
Jun 12
🧬 TWEETORIAL/X'torial: Why Every Rare Cancer Patient Deserves Molecular Profiling 🧬
1/15 🚨 Here's a shocking fact: Rare cancers make up 25% of ALL cancer cases, yet most patients never get the molecular testing that could save their lives.
👉In our policy & practice paper - 20th anniversary of @JCOOP_ASCO @ASCO @JCO_ASCO Our position 👉 Comprehensive molecular profiling must be standard care for rare cancers 🦓-#RareCancer #precisionMedicine Let's dive in @OncoAlert @Dr_R_Kurzrock 🧵
Free Link: ascopubs.org/doi/10.1200/OP…Image
2/15 📊 The numbers are staggering:
~200 types of rare/ultra-rare cancers exist
Rare = <15 per 100,000 people
Ultra-rare = <1 per million/year
Yet together they affect MILLIONS of patients worldwide
Each deserves a fighting chance. 💪ascopubs.org/doi/10.1200/OP…
3/15 🎯 Here's the game-changer: The FDA has approved 9 tissue-agnostic therapies that work across cancer types based on molecular features, not where the cancer started.
But here's the catch - you can ONLY access them if your tumor gets molecular profiling (NGS). 🔬acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…
Read 16 tweets
Vivek Subbiah, MD Profile picture
Jun 4
🚨 @ASCO #ASCO25 was absolutely incredible! 🧬✨ So many groundbreaking advances in oncology and exciting publications that are going to change patient care.
👉Sharing the key ones below @TheLancet @TheLancetOncol @JCO_ASCO @JAMA_current @JAMAOnc @CD_AACR - Also added the 10+ simultaneous @NEJM links
👉What other important studies from #ASCO25 should be on everyone's radar? @OncoAlert
Please add any I missed! 👇
1/ Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial @TheLancet @oncodaily @ASCO #ASCO25 thelancet.com/journals/lance…
2/Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study @TheLancet thelancet.com/journals/lance…
Read 20 tweets
Vivek Subbiah, MD Profile picture
Jun 3
🚨 Wow! #ASCO25 @ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert
1 /Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy @g_mountzios @OncoAlert #ASCO25 @ASCO
nejm.org/doi/full/10.10…
2/ Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma @NEJM #ASCO25 @ASCO
nejm.org/doi/full/10.10…
Read 14 tweets
Vivek Subbiah, MD Profile picture
May 29
💥🚨 A tweetorial/ X'torial on the paper published today "Tissue-agnostic cancer therapies: promise, reality, and the path forward"
@NatureComms @NaturePortfolio
👉The Future of Cancer Treatment is Here: Tissue-Agnostic Therapies @OncoAlert @ASCO #ASCO25
A Thread 🧵 1/15
nature.com/articles/s4146…
2/ What if we treated cancer based on its MOLECULAR drivers instead of where it started in the body?
This isn't science fiction—it's tissue-agnostic therapy, and it's revolutionizing oncology 🚀

#PrecisionMedicine #CancerResearch nature.com/articles/s4146…Image
3/ 📊 THE NUMBERS:
9 FDA-approved tissue-agnostic therapies
3 categories: Targeted therapies, immunotherapies, antibody-drug conjugates
Pembrolizumab made history in 2017 as the first approval
These treat 30+ cancer types based on biomarkers, not tumor location 🎯
nature.com/articles/s4146…
Read 16 tweets
Vivek Subbiah, MD Profile picture
Jan 2
🚨🥁🥁🥁By popular demand, I’m pleased to share the top Precision Oncology papers of 2024! 📚✨
#HappyNewYear2025
👉Please feel free to add your favorite papers to the X thread. Let’s celebrate the advancements in our field together & looking forward for ground breaking advances in 2025! #PrecisionOncology #TopPapers2024 @OncoAlert 1/nImage
1/n The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development #TissueAgnostic #PrecisionMedicine
👉The ESMO PMWG proposes a framework to foster and accelerate tumour-agnostic drug development for patients with cancer @BenWestphalen @GPentheroudakis @curijoey @FAndreMD @myESMO @Annals_Oncology
annalsofoncology.org/article/S0923-…Image
2/n Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
This represents the perfect marriage of the field of genomics and immunology. Combined Immunecheckpoint therapy in MSI-H cancers @NEJM @MyriamChalabi @DrChoueiri

nejm.org/doi/full/10.10…
Read 18 tweets
Vivek Subbiah, MD Profile picture
Jan 2, 2024
🚨Artificial intelligence #AI is poised to shape medicine, oncology research & cancer care in the next decade.
📍Presenting the "Top AI in Oncology articles of 2023"
👉Remember, this list isn't exhaustive!
👉Feel free to Tag, add, tweet, X & share your must-reads with this list. Let's keep the knowledge flowing!
#AI #artificialintelligence #PrecisionMedicine #PrecisionOncology #genomics #immunotherapy
@OncoAlert @sama #chatgpt4 @TargetedOnc @OncLive @gotoPER @FDAOncology @OncBrothers @oncodaily @Annals_Oncology @NEJM @NEJM_AI @JAMAOnc @Nature @NatureMedicine @JCO_ASCO @TheUSONetwork @SarahCannonDocs 🧵Image
There is an urgent need to reinvigorate clinical trials through drug discovery, interpreting imaging, streamlining electronic health records, and improving workflow, over time advancing public health. AI can aid in many of these aspects in all stages of drug development.
👉Timeline of drug development from the present to the future @naturemedicine
nature.com/articles/s4159…Image
Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study
👉AI lowered screen-reading workload #AI @TheLancetOncol
thelancet.com/journals/lanon…
Read 17 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(